Edition:
United States

C R Bard Inc (BCR)

BCR on New York Consolidated

308.59USD
25 May 2017
Change (% chg)

$0.15 (+0.05%)
Prev Close
$308.44
Open
$308.70
Day's High
$309.01
Day's Low
$307.85
Volume
609,720
Avg. Vol
862,575
52-wk High
$309.16
52-wk Low
$203.63

BCR

Chart for BCR

About

C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended... (more)

Overall

Beta: 0.64
Market Cap(Mil.): $22,336.36
Shares Outstanding(Mil.): 72.42
Dividend: 0.26
Yield (%): 0.34

Financials

  BCR Industry Sector
P/E (TTM): 39.22 31.25 17.42
EPS (TTM): 7.87 -- --
ROI: 15.89 12.78 -5.45
ROE: 37.70 15.27 -4.73

BRIEF-Becton Dickinson and Co entered into a three-year term loan agreement

* On May 12, 2017, Becton Dickinson and Company entered into a three-year term loan agreement - SEC filing

May 16 2017

BRIEF-BD announces exercise of option to purchase additional shares by underwriters of public equity offerings

* BD announces exercise of option to purchase additional shares by underwriters of public equity offerings increasing total gross proceeds to $4.95 billion

May 12 2017

BRIEF-Becton Dickinson announces commencement of exchange offers and consent solicitations

* BD announces commencement of exchange offers and consent solicitations for C. R. Bard Inc notes

May 05 2017

Lackluster $24 bln medical merger better than none

NEW YORK (Reuters Breakingviews) - Obamacare lives on. Republican U.S. lawmakers haven't yet repealed the Affordable Care Act, as it's formally known. Healthcare companies have to live with it, too. Becton Dickinson's $24 billion deal to buy C.R. Bard is one result. The expected cost savings fall well short of justifying the 25 percent premium. But scale brings needed negotiating power selling needles and catheters to hospitals.

Apr 24 2017

Becton Dickinson to acquire Bard for $24 billion

NEW YORK U.S. medical equipment supplier Becton Dickinson and Co will acquire C R Bard Inc, in a $24 billion cash-and-stock deal, adding Bard's devices to its portfolio in the high-growth sectors of oncology and surgery, both companies said on Sunday. | Video

Apr 24 2017

BRIEF-Becton Dickinson to buy Bard for $24 billion

* Deal immediately accretive and expected to generate high single-digit accretion to adjusted EPS in fiscal year 2019 to Becton Dickinson

Apr 23 2017

BRIEF-C R Bard CEO Timothy Ring's FY 2016 compensation $12.63 mln vs $11.74 mln in FY 2015

* Ceo timothy ring's fy 2016 total compensation $12.63 million versus $11.74 million in fy 2015 - sec filing

Mar 15 2017

More From Around the Web

Earnings vs. Estimates